The incidence of allergies is increasing, particularly in industrialized areas. Allergic inflammation can differ substantially in intensity. Traditional drug therapy such as antihistamines, corticosteroids, anticholinergic agents and leukotriene inhibitors is important in reducing and preventing symptoms and is essential in acute use. More recent therapies including anti-immunoglobin E (IgE) therapy, anti-interleukin (IL) monoclonal antibodies, and phosphodiesterase 4/phospholipaseA2 inhibitors, have improved outcomes. However, in order to develop more effective therapies, further research is needed into the molecular mechanisms underlying allergy onset, particularly in terms of intracellular reactions and the cytosolic Ca2+ balance.
Browse our selection of video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and a selection of peer-reviewed articles from the journal portfolio.
Our supporting partners do not constitute an endorsement of the content on this page.
Allergic Conditions Content
William R. Lumry, AAAAI 2023: Lanadelumab for paediatric patients aged 2 to <12 years with hereditary angioedema – the SPRING Study
The SPRING Study (NCT04070326) was a phase 3 study that investigated the safety, pharmacokinetics, and pharmacodynamics of lanadelumab for prevention of hereditary angioedema (HAE) attacks in children. touchIMMUNOLOGY were delighted to speak with Dr. William R. Lumry (UT Southwestern Medical Center, TX, USA) around the aims, design and findings from the SPRING Study and how […]
William R. Lumry, AAAAI 2023: Current treatment paradigm and unmet needs in hereditary angioedema
Hereditary angioedema (HAE) is a rare genetic disease that reduces C1 inhibitor levels and impacts the regulation of several pathways involved in dilation of the blood vessels and results in recurrent episodes of severe swelling. touchIMMUNOLOGY were delighted to speak with Dr. William R. Lumry (UT Southwestern Medical Center, TX, USA) around the unmet needs […]
Ralph Mösges, AAAAI 2023: Mannan conjugated birch pollen allergoids for the treatment of birch pollen allergy
Mannan conjugated birch pollen allergoids are an immunotherapy currently under clinical investigation for the treatment of birch pollen allergy. touchIMMUNOLOGY caught up with Prof. Ralph Mösges (University of Cologne, Cologne, Germany) to discuss the rationale and methodology of the the clinical trial programme for Mannan conjugated birch pollen allergoids, the efficacy and safety findings so […]
Ralph Mösges, AAAAI 2023: Immunotherapy for the treatment of birch pollen allergy
Allergen immunotherapy aims to treat an allergic response by reducing the production of IgE antibodies by the immune system, this is done by desensitising the patient to the allergen extract. It was a pleasure to talk with Prof. Ralph Mösges (University of Cologne, Cologne, Germany) around the impact immunotherapy has already had on the treatment […]
Luis Felipe C. Ensina, AAAAI 2023: Ligelizumab for the treatment of chronic spontaneous urticaria – findings from PEARL-1 and PEARL-2
Ligelizumab is a monoclonal antibody recently investigated in the phase 3 PEARL-1 and PEARL-2 studies for the treatment of chronic spontaneous urticaria (ClinicalTrials.gov Identifiers: NCT03580369 & NCT03580356). In this touchIMMUNOLOGY interview, we spoke with Dr. Luis Felipe C. Ensina (Federal University of São Paulo, São Paulo, Brazil) around the rationale for investigating ligelizumab in this […]
Luis Felipe C. Ensina, AAAAI 2023: Treatment options and unmet needs in chronic spontaneous urticaria
Chronic spontaneous urticaria (CSU) is a skin condition defined by the spontaneous presence of hives for prolonged periods of time and angioedema. There is no known cause however CSU has been linked to the immune system and autoimmune conditions. touchIMMUNOLOGY were delighted to speak with Dr. Luis Felipe C. Ensina (Federal University of São Paulo, […]
Management of severe paediatric asthma: From hospital to home
Members of the MDT and a patient advocate discuss the optimal management of severe asthma in children
- Recall the diagnostic workup for severe type 2 asthma in children
- Explain the pathophysiology of severe type 2 asthma and how this can guide treatment decisions
- Discuss the importance of the MDT in optimizing the management of children with severe asthma
Improving outcomes in severe paediatric asthma: New treatments, new possibilities
Watch an asthma expert and a primary care respiratory specialist discuss diagnosis, treatment and management of severe asthma in children.
- Recall the symptoms associated with severe asthma in children
- Summarize the clinical evidence supporting the use of biologics in children with severe asthma
- Describe the optimal long-term management of children with severe asthma
What’s new for eosinophilic oesophagitis? A case-based discussion of patient care
Watch experts give their perspective on different aspects of managing patients with EoE, based on clinical case studies.
- Describe the complex pathophysiology of EoE and how this manifests as clinical symptoms throughout life
- Distinguish eosinophilic oesophagitis as a progressive disease that is distinct from GORD
- Summarize the clinical evidence supporting the use of emerging biologic treatments for EoE
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!